Annual Revenue Comparison: Ascendis Pharma A/S vs Corcept Therapeutics Incorporated

Biotech Revenue Race: Ascendis vs. Corcept from 2014-2023

__timestampAscendis Pharma A/SCorcept Therapeutics Incorporated
Wednesday, January 1, 20141398300026551000
Thursday, January 1, 2015811800050286000
Friday, January 1, 2016460600081321000
Sunday, January 1, 20171530000159201000
Monday, January 1, 201810581000251247000
Tuesday, January 1, 201913375000306486000
Wednesday, January 1, 20206953000353874000
Friday, January 1, 20217778000365978000
Saturday, January 1, 202251174000401858000
Sunday, January 1, 2023266718000482375000
Monday, January 1, 2024363641000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the competitive world of biotechnology, Ascendis Pharma A/S and Corcept Therapeutics Incorporated have charted distinct paths over the past decade. From 2014 to 2023, Corcept Therapeutics has consistently outperformed Ascendis Pharma in terms of revenue, showcasing a robust growth trajectory. Starting with a modest revenue of approximately $27 million in 2014, Corcept Therapeutics saw a remarkable increase, reaching nearly $482 million by 2023. This represents an impressive growth of over 1,700%.

In contrast, Ascendis Pharma began with a revenue of around $14 million in 2014, experiencing a significant surge to approximately $267 million by 2023. This growth, while substantial at over 1,800%, still trails behind Corcept's overall revenue figures. The data highlights the dynamic nature of the biotech industry, where strategic decisions and market positioning can lead to varied financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025